Evidence map›Paper›PMID 42477846›Full record

ArticleJournal of intensive care2026

Early osmotherapy exposure and subsequent incident acute kidney injury in neurocritical care patients: a MIMIC-IV retrospective cohort study.

Shenshen Du, Shaojie Zhang, Weicheng Lai, Qimeng Wu, Shuang Cui, Shuqi Xu, Bo Hu

Abstract read
In one paragraph

Article in Journal of intensive care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shenshen Du *Department of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Shaojie Zhang *Department of Neurosurgery, General Hospital of the Yangtze River Shipping/Wuhan Brain Hospital, No. 5 Huiji Road, Jiang'an District, Wuhan, 430014, Hubei, China.
Weicheng Lai *Department of Cardiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine,Tsinghua Medicine, Tsinghua University, Beijing, 102218, China.
Qimeng Wu *Department of Nephrology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, Guangdong, China.
Shuang CuiDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Shuqi XuDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China.
Bo HuDepartment of Nephrology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, China. hubojnu2026@163.com.

Funding

Guangzhou Science and Technology Program Project SL2024A03J00769Youth S&T Talent Support Programme of Guangdong Provincial Association for Science and Technology SKXRC2025221
6 · The paper itself

Abstract

backgroundOsmotherapy is frequently used in neurocritical care to manage cerebral edema and intracranial hypertension. However, its association with subsequent new-onset acute kidney injury (AKI), and whether early serum sodium or chloride burden materially attenuates this association, remain uncertain.

methodsWe conducted a retrospective cohort study using MIMIC-IV version 3.1. Adult first-ICU neurocritical care patients were analyzed with a 48-h landmark design. The primary risk set included patients who were alive, remained in the ICU, and were AKI-free at 48 h after ICU admission. The primary exposure was any osmotherapy, defined as mannitol or hypertonic saline administered within the first 48 ICU hours, compared with no osmotherapy. The primary outcome was incident AKI after the 48-h landmark through ICU day 7 or ICU discharge. Multivariable regression was used as the main adjusted model; propensity-score weighting, overlap weighting, doubly robust models, and modified Poisson regression were used as complementary estimators. Sodium/chloride burden analyses were conducted in the lab-complete subset.

resultsThe final 48-h landmark cohort included 2,756 adult neurocritical care patients, of whom 624 (22.6%) developed incident AKI after the landmark. Any osmotherapy was administered to 365 patients (13.2%). In the doubly robust overlap-weighted logistic model, any osmotherapy was associated with subsequent incident AKI (OR, 1.48; 95% CI 1.12-1.96; P = 0.006). The corresponding doubly robust overlap-weighted modified Poisson estimate was RR 1.30 (95% CI 1.08-1.57; P = 0.006). Sodium/chloride burden analyses included 2,455 lab-complete patients. Early sodium burden (OR, 0.99; 95% CI 0.92-1.07; P = 0.792) and chloride burden (OR, 1.01; 95% CI 0.94-1.09; P = 0.743) did not materially attenuate the observed association in exploratory adjustment models. In exploratory clinical relevance analyses, patients with subsequent AKI had higher hospital mortality and lower creatinine-based renal recovery at ICU and hospital discharge. Dose-proxy and hypertonic saline concentration-specific analyses were exploratory because dose capture was incomplete and 23.4% hypertonic saline exposure was sparse.

conclusionsAmong adult neurocritical care patients who were alive, remained in the ICU, and were AKI-free at the 48-h landmark, early osmotherapy exposure was associated with a higher risk of subsequent incident AKI. This association was not materially attenuated by early serum sodium or chloride burden in exploratory adjustment models. These findings support careful renal monitoring in patients receiving clinically indicated osmotherapy, while residual confounding by indication precludes causal interpretation.

Indexed as

Acute kidney injuryChloride burdenHypertonic salineLandmark analysisMannitolMIMIC-IVNeurocritical careOsmotherapySodium burden

Identifiers

PMID42477846
PMCPMC13390403

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.